JP6343135B2 - 血中のユビキノール活性化剤及び体内の酸化ストレス度低減剤 - Google Patents
血中のユビキノール活性化剤及び体内の酸化ストレス度低減剤 Download PDFInfo
- Publication number
- JP6343135B2 JP6343135B2 JP2013208048A JP2013208048A JP6343135B2 JP 6343135 B2 JP6343135 B2 JP 6343135B2 JP 2013208048 A JP2013208048 A JP 2013208048A JP 2013208048 A JP2013208048 A JP 2013208048A JP 6343135 B2 JP6343135 B2 JP 6343135B2
- Authority
- JP
- Japan
- Prior art keywords
- test
- oxidative stress
- lactic acid
- blood
- mitochondrial function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000036542 oxidative stress Effects 0.000 title claims description 15
- 239000008280 blood Substances 0.000 title claims description 4
- 210000004369 blood Anatomy 0.000 title claims description 4
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 title claims description 4
- 239000003638 chemical reducing agent Substances 0.000 title claims description 3
- 229940040064 ubiquinol Drugs 0.000 title claims description 3
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 title claims description 3
- 239000012190 activator Substances 0.000 title claims 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 description 21
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 230000004898 mitochondrial function Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 230000003712 anti-aging effect Effects 0.000 description 11
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- 238000009833 condensation Methods 0.000 description 7
- 230000005494 condensation Effects 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(1)カラム:内径4.6mm、長さ15cmのODSカラムを用いる。
(2)溶離液:トリフルオロ酢酸を0.002重量%の割合で溶解した蒸留水(A液)とアセトニトリル(B液)を組み合わせて用いる。
(3)溶出プログラム:溶出開始(0分)から5分経過する時点まではA液/B液=75容量%/25容量%の一定比率で溶離液を流し、溶出開始後5分経過する時点から35分経過する時点まではA液/B液=75容量%/25容量%からA液/B液=0容量%/100容量%に変化するリニアグラジュエント溶出を行ない、溶出開始後35分経過する時点から40分経過する時点まではA液/B液=0容量%/100容量%の一定比率で溶離液を流す。
(4)溶離液の流量:1.0ml/min
(5)検出:210nmの紫外波長を用いた紫外吸光法により検出する。
(1)二標本検定(分散分析、t検定、Wilcoxon/Kruskal−Wallis検定);群間比較
(2)二標本検定(一元配置の分散分析、平均値のt検定);群内比較
(1)2標本検定(分散分析、t検定、Wilcoxon/Kruskal−Wallis検定);群間比較では、ミトコンドリア機能の亢進度合いを示すCoQH活性およびtotal(CoQH+CoQ10)活性が、各々図1および図2に示されているように、有意(p<0.05)に向上することを示した。表2はCoQH活性の変化量を、表3はtotalの変化量を各々示している。
Claims (2)
- L−乳酸の縮合物であるオリゴ乳酸を有効成分とする血中のユビキノール活性化剤。
- L−乳酸の縮合物であるオリゴ乳酸を有効成分とする体内の酸化ストレス度低減剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013208048A JP6343135B2 (ja) | 2013-10-03 | 2013-10-03 | 血中のユビキノール活性化剤及び体内の酸化ストレス度低減剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013208048A JP6343135B2 (ja) | 2013-10-03 | 2013-10-03 | 血中のユビキノール活性化剤及び体内の酸化ストレス度低減剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015071563A JP2015071563A (ja) | 2015-04-16 |
JP6343135B2 true JP6343135B2 (ja) | 2018-06-13 |
Family
ID=53014235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013208048A Active JP6343135B2 (ja) | 2013-10-03 | 2013-10-03 | 血中のユビキノール活性化剤及び体内の酸化ストレス度低減剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6343135B2 (ja) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3652865B2 (ja) * | 1997-12-17 | 2005-05-25 | 株式会社Glart | 乳酸縮合物の混合物及びそれを含有する組成物 |
US6734214B1 (en) * | 1999-08-09 | 2004-05-11 | Amato Pharmaceutical Products, Ltd. | Remedies for diabetes |
-
2013
- 2013-10-03 JP JP2013208048A patent/JP6343135B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015071563A (ja) | 2015-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nieman et al. | Immunometabolism: a multi-omics approach to interpreting the influence of exercise and diet on the immune system | |
Pastor et al. | Resveratrol, human health and winemaking perspectives | |
Arrick et al. | Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats | |
Bailey et al. | Increased cerebral output of free radicals during hypoxia: implications for acute mountain sickness? | |
Kim et al. | Effects of lycopene supplementation on oxidative stress and markers of endothelial function in healthy men | |
Trela et al. | Resveratrol: isomeric molar absorptivities and stability | |
Guo et al. | Effects of polyphenol, measured by a biomarker of total polyphenols in urine, on cardiovascular risk factors after a long-term follow-up in the PREDIMED study | |
de Paula Martins et al. | Neopterin preconditioning prevents inflammasome activation in mammalian astrocytes | |
Nair et al. | Evaluation of in vitro antidiabetic activity of selected plant extracts | |
McIlvenna et al. | Beetroot juice versus chard gel: a pharmacokinetic and pharmacodynamic comparison of nitrate bioavailability | |
Domanico et al. | Circulating levels of reactive oxygen species in patients with nonproliferative diabetic retinopathy and the influence of antioxidant supplementation: 6-month follow-up | |
Al-Daghri et al. | Hypovitaminosis D and cardiometabolic risk factors among non-obese youth | |
Vlassopoulos et al. | Protein–phenolic interactions and inhibition of glycation–combining a systematic review and experimental models for enhanced physiological relevance | |
Aman et al. | Antioxidant activity of thymol: protective role in AAPH-induced hemolysis in diabetic erythrocytes | |
Kaliora et al. | The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention | |
Amponsah-Offeh et al. | Oxidative stress, antioxidants and hypertension | |
Decroix et al. | One-week cocoa flavanol intake increases prefrontal cortex oxygenation at rest and during moderate-intensity exercise in normoxia and hypoxia | |
Asgary et al. | Effect of fresh orange juice intake on physiological characteristics in healthy volunteers | |
West et al. | Antiglycation activity of iridoids and their food sources | |
WO2005085843A1 (ja) | 唾液分析による脂溶性ビタミン及び/又は脂溶性フードファクターの検査方法 | |
Pawełczyk et al. | Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: findings from the OFFER randomized controlled study | |
Li et al. | Pilot study: nutritional and preclinical safety investigation of fermented hispidin-enriched Sanghuangporus sanghuang mycelia: a promising functional food material to improve sleep | |
JP6773951B2 (ja) | 唾液試料の調製方法 | |
Šadzevičienė et al. | Inhibition of peripheral blood neutrophil oxidative burst in periodontitis patients with a homeopathic medication Traumeel S | |
Ghayour-Mobarhan et al. | Serum selenium and glutathione peroxidase in patients with obesity and metabolic syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170321 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170719 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180413 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180501 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180518 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6343135 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |